Akums Drugs and Pharmaceuticals (NSE:AKUMS) ROCE % : 15.27% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Akums Drugs and Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Akums Drugs and Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was 15.27%.

Akums Drugs and Pharmaceuticals ROCE % Historical Data

The historical data trend for Akums Drugs and Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akums Drugs and Pharmaceuticals ROCE % Chart

Akums Drugs and Pharmaceuticals Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

ROCE %

11.26

-10.45

10.34

0.23

Akums Drugs and Pharmaceuticals Semi-Annual Data
	Mar21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial			11.29	9.48	-4.48	4.62	15.27

Akums Drugs and Pharmaceuticals ROCE % Calculation

Akums Drugs and Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	49.73	/	( ( (32665.27 - 12655.67)	+	(35163.65 - 12105.52) )	/ 2 )
	=	49.73	/	( (20009.6	+	23058.13)	/ 2 )
	=	49.73	/	21533.865
	=	0.23 %

Akums Drugs and Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	4079.76	/	( ( (35163.65 - 12105.52)	+	(42704.03 - 12328.77) )	/ 2 )
	=	4079.76	/	( ( 23058.13	+	30375.26 )	/ 2 )
	=	4079.76	/	26716.695
	=	15.27 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

Akums Drugs and Pharmaceuticals (NSE:AKUMS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Akums Drugs and Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS) » Definitions » ROCE %

Traded in Other Exchanges

544222:India

Address

Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083

Website

https://www.akums.in

Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).

Akums Drugs and Pharmaceuticals Headlines

No Headlines